Valsartan Lawsuit Requests Class Action Status Over Recall

valsartan lawsuit

A new valsartan lawsuit is seeking class action status over recalled pills from numerous manufacturers who sold and distributed generic versions of the hypertension drug that were contaminated with carcinogenic impurities.

James Jones filed the complaint in the Eastern District of Missouri on September 11. According to the valsartan lawsuit, putative class members paid full price for valsartan pills that were worthless due to contamination with the dangerous and carcinogenic N-nitrosodimethylamine (NDMA) and are now facing incidental medical expenses.

The lawsuit names Zhejiang Huahai Pharmaceutical Co., Prinston Pharmaceutical, Inc., Solco Healthcare U.S. LLC, and Huahai US, Inc. as defendants. Jones is requesting class action status for all individuals who purchased the contaminated valsartan drugs and received advisement to discontinue using them due to impurities.

Valsartan Lawsuit Background

The European Health Products Regulatory Authority (HPRA) issued the first valsartan recalls July 5, after batches of the active ingredient from Zhejiang Huahai Pharmaceuticals in China tested positive for NDMA, which can increase the risk of numerous types of cancer. This initial recall affected about 2,300 batches of valsartan and valstartan HCTV throughout Europe and Canada. The same drug company was responsible for the Torrent Pharmaceutical pills recall.

The FDA followed close behind with its own recall July 13, announcing that the regulatory agency had launched its own investigation to determine the contamination’s scope and the risk to consumers.

According to Jones, he and other plaintiffs bought the drugs on the pretense that they were safe and now must undergo regular cancer monitoring because of the contamination.

“Plaintiff and the putative class members were injured by the full purchase price of their valsartan-containing medications and incidental medical expenses,” Jones indicated. “These medications are worthless, as they are contaminated with carcinogenic and harmful N-nitrosodimethylamine and are not fit for human consumption.”

Jones is presenting claims of failure to warn, unjust enrichment, strict product liability, fraudulent concealment, negligence, breach of contract, breach of implied warranty of merchantability, and gross negligence.

The FDA has allocated a group of pharmacists and nurses to answer consumers’ questions regarding the recalls. Since the initial recalls, the agency has received more than 6,000 such inquiries from doctors, nurses, patients, pharmacists, and academics. For more information, interested parties can call (855) 543-3784 or email druginfo@fda.hhs.gov.

The valsartan lawsuit request for class action status comes amidst a quickly escalating number of individual valsartan cancer lawsuits being pursued by individuals nationwide. These include claims for kidney cancer, liver cancer, and other digestive tract cancers.